AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase II clinical study titled ‘A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn’s Disease and an Ileostomy (CALLISTO).’ The study aims to assess the safety, tolerability, and mucosal repair effects of AZD7798 compared to a placebo in patients with active ileal Crohn’s disease and an ileostomy.
Intervention/Treatment: The study tests the drug AZD7798, an experimental treatment intended to improve mucosal repair in Crohn’s disease patients, against a placebo.
Study Design: This interventional study employs a randomized, parallel-group design with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary goal is to evaluate the drug’s safety and effectiveness over a 12-week induction period, followed by a 40-week open-label maintenance phase.
Study Timeline: The study began on December 11, 2024, with primary completion expected after the 12-week induction phase. The last update was submitted on July 15, 2025, indicating ongoing recruitment and progress.
Market Implications: This study update could positively influence AstraZeneca’s stock performance by demonstrating the company’s commitment to innovative treatments in the gastrointestinal sector. Success in this trial may enhance investor confidence and position AstraZeneca favorably against competitors in the Crohn’s disease treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.